July 12, 2010 |
More than 100,000 women each year are diagnosed with a type of breast cancer called postmenopausal estrogen receptor-positive -- the most common type of breast cancer. Studies in recent years have shown that an important tool to prevent recurrence of this type of breast cancer lies in the use of medications called aromatase inhibitors. On Monday, cancer experts issued guidelines updating the knowledge about aromatase inhibitors -- which are medications that lower estrogen -- and how women and their doctors should best utilize this class of drugs.
March 11, 2008
Taking the breast cancer pill Femara can significantly reduce the chances that a woman's cancer will return, even long after she has stopped taking the estrogen blocker tamoxifen, researchers said in Chicago. They said post-menopausal women who took Femara from one to seven years after finishing a five-year regimen of tamoxifen reduced by 63% the risk the cancer would come back. The study results were published in the Journal of Clinical Oncology.
September 23, 2013 |
Women with a higher-than-usual risk for developing breast cancer should consider taking one of two medications approved by the Food and Drug Administration to reduce that risk, a federal panel has concluded. But the medications, which can raise a woman's risk of developing blood clots, are not for everyone and should not be taken for breast cancer reduction by most women, the U.S. Preventive Services Task Force said. Taken daily by women who are more likely than most to develop breast cancer, the chemotherapy drug tamoxifen or the osteoporosis drug raloxifene have been shown to drive down that risk.
January 25, 2011 |
The breast cancer drug tamoxifen may stall the progression of non-small cell lung cancer in those who take it after breast cancer treatment, a new study has found. Tamoxifen is the oldest of a wide array of medications that block the action of the hormone estrogen in the body. Researchers have found growing evidence in recent years that the majority of non-small cell lung cancers -- the most common form of lung cancer -- respond to estrogen with growth. So they wondered whether women taking tamoxifen as an adjunct to their breast cancer treatment might be less likely to develop or die of lung cancer.
February 5, 2007
Regarding your Jan. 29 article on side effects from breast cancer drugs ["Cancer Drugs: Too Toxic?"], I began taking Arimidex two years ago. Five days after I started the prescription, I woke up in the middle of the night with excruciating pain in my hands. I thought it would diminish over time, but it didn't. The diagnosis, finally? Carpal tunnel syndrome. Surgery was suggested. I had been a legal secretary for more than 30 years, typed five days a week and never got carpal tunnel syndrome.
August 10, 1998 |
If you are lucky, this is the way cancer treatment ends, not with a bang but a whimper. Let's see, of the treatments listed for me in November: chemo--it's done; surgery--done; radiation--done. It remained only to go see my oncologist, Dr. James Waisman, of whom I am preposterously fond, to ask the musical question, "Is that all there is?" And so, it seems, yes. "In my mind"--he nonchalantly shrugged--"you're cured." Oh. Just like that. Is that really all there is?